Taysha Gene Therapies, Inc.
TSHA
$6.86
$0.010.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -52.27% | 14.91% | -21.77% | -24.86% | -14.61% |
| Total Depreciation and Amortization | -1.34% | 4.55% | 3.25% | -2.12% | -6.91% |
| Total Amortization of Deferred Charges | -- | -100.00% | -- | -- | -- |
| Total Other Non-Cash Items | -25.45% | 92.59% | -2.24% | 10.97% | 36.34% |
| Change in Net Operating Assets | 34.19% | -275.44% | 81.09% | 148.86% | -75.16% |
| Cash from Operations | -52.98% | -10.58% | -19.74% | 8.35% | -20.28% |
| Capital Expenditure | 90.40% | -131.48% | -5,300.00% | 99.47% | -19,000.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100,100.00% | -95.00% | -6.25% | 814.29% | -36.36% |
| Cash from Investing | -1,124.29% | -414.58% | -177.42% | 116.71% | -2,953.85% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -98.61% | -- | -- | 288,126.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 133.33% | 78.97% | -329.66% | 192.91% | -395.35% |
| Cash from Financing | -98.57% | 463.33% | -95.93% | 416,038.46% | 85.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -291.22% | 246.51% | -107.86% | 974.07% | -20.32% |